Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...
The following is a summary of “Ability to return to work and persistent symptoms six months after viral meningitis – a ...
US regulators have approved a new meningitis vaccine developed by GSK, sparking cautious optimism for the sector in the wake of Donald Trump's election for a second term as President.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback